Medicare Beneficiaries' Perspectives on the Quality of Hospital Care and Their Implications for Value-Based Payment.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 06 2023
Historique:
medline: 23 6 2023
pubmed: 21 6 2023
entrez: 21 6 2023
Statut: epublish

Résumé

Medicare's Hospital Value-Based Purchasing (HVBP) program adjusts hospital payments according to performance on 4 equally weighted quality domains: clinical outcomes, safety, patient experience, and efficiency. The assumption that performance on each domain is equally important may not reflect the preferences of Medicare beneficiaries. To estimate the relative importance (ie, weight) of the 4 quality domains in the HVBP program from the perspective of Medicare beneficiaries and the impact of using beneficiary value weights on incentive payments for hospitals enrolled in fiscal year 2019. An online survey was conducted in March 2022. A nationally representative sample of Medicare beneficiaries was recruited through Ipsos KnowledgePanel. Value weights were estimated using a discrete choice experiment that asked respondents to choose between 2 hospitals and indicate which they preferred. Hospitals were described using 6 attributes, including (1) clinical outcomes, (2) patient experience, (3) safety, (4) Medicare spending per patient, (5) distance, and (6) out-of-pocket cost. Data analysis was performed from April to November 2022. An effects-coded mixed logit regression model was used to estimate the relative importance of quality domains. HVBP program performance was linked to Medicare payment data in the Medicare Inpatient Hospitals by Provider and Service data set and hospital characteristics from the American Hospital Association Annual Survey data set, and the estimated impact of using beneficiary value weights on hospital payments was estimated. A total of 1025 Medicare beneficiaries (518 women [51%]; 879 individuals [86%] aged ≥65 years; 717 White individuals [70%]) responded to the survey. A hospital's performance on clinical outcomes was most highly valued by beneficiaries (49%), followed by safety (22%), patient experience (21%), and efficiency (8%). Nearly twice as many hospitals would see a payment reduction when using beneficiary value weights than would see an increase (1830 vs 922 hospitals); however, the average net decrease was smaller (mean [SD], -$46 978 [$71 211]; median [IQR], -$24 628 [-$53 507 to -$9562]) than the comparable increase (mean [SD], $93 243 [$190 654]; median [IQR], $35 358 [$9906 to $97 348]). Hospitals seeing a net reduction with beneficiary value weights were more likely to be smaller, lower volume, nonteaching, and non-safety-net hospitals located in more deprived areas that served less complex patients. This survey study of Medicare beneficiaries found that current HVBP program value weights do not reflect beneficiary preferences, suggesting that the use of beneficiary value weights may exacerbate disparities by rewarding larger, high-volume hospitals.

Identifiants

pubmed: 37342041
pii: 2806323
doi: 10.1001/jamanetworkopen.2023.19047
pmc: PMC10285577
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2319047

Subventions

Organisme : AHRQ HHS
ID : R03 HS027853
Pays : United States

Références

Value Health. 2020 Jul;23(7):851-861
pubmed: 32762986
JAMA Health Forum. 2022 May 13;3(5):e221006
pubmed: 35977255
Health Aff (Millwood). 2021 Jan;40(1):138-145
pubmed: 33400583
Health Aff (Millwood). 2014 Jun;33(6):988-96
pubmed: 24889948
N Engl J Med. 2015 Mar 5;372(10):897-9
pubmed: 25622024
Med Decis Making. 2022 Jan;42(1):51-59
pubmed: 34041964
N Engl J Med. 2022 Jul 14;387(2):97-99
pubmed: 35801977
Med Care Res Rev. 2020 Dec;77(6):511-537
pubmed: 31216945
Front Pharmacol. 2021 Jun 24;12:690021
pubmed: 34248638
Health Serv Res. 2015 Dec;50 Suppl 2:2057-89
pubmed: 26549041
Soc Sci Med. 2016 Aug;162:59-67
pubmed: 27337350
JAMA. 2021 Jun 22;325(24):2439-2440
pubmed: 34086054
JAMA. 2017 Nov 7;318(17):1668-1678
pubmed: 29114831
Pharmacoeconomics. 2019 Feb;37(2):201-226
pubmed: 30392040
Health Serv Res. 2018 Dec;53(6):4477-4490
pubmed: 30136284
JAMA. 2017 Apr 11;317(14):1461-1470
pubmed: 28324029
Value Health. 2011 Jun;14(4):403-13
pubmed: 21669364
BMJ Qual Saf. 2019 Apr;28(4):338-344
pubmed: 30100565
Med Care. 2020 Aug;58(8):734-743
pubmed: 32692140
Value Health. 2017 Jun;20(6):834-836
pubmed: 28577702
JAMA Surg. 2021 Aug 1;156(8):785-786
pubmed: 33825811
JAMA. 2018 Mar 13;319(10):1024-1039
pubmed: 29536101
JAMA. 2021 Mar 23;325(12):1219-1221
pubmed: 33755063
JAMA. 2013 Jan 23;309(4):342-3
pubmed: 23340629
Value Health. 2017 Feb;20(2):286-291
pubmed: 28237211
JAMA. 2017 Mar 21;317(11):1107-1108
pubmed: 28324079
N Engl J Med. 2018 Jun 28;378(26):2456-2458
pubmed: 29949490
Circ Cardiovasc Qual Outcomes. 2012 Mar 1;5(2):148-9
pubmed: 22438462
Fed Regist. 2011 May 6;76(88):26490-547
pubmed: 21548401
Curr Hematol Malig Rep. 2016 Aug;11(4):303-10
pubmed: 27262855
N Engl J Med. 2010 Dec 23;363(26):2477-81
pubmed: 21142528
Health Aff (Millwood). 2003 Nov-Dec;22(6):183-90
pubmed: 14649445
N Engl J Med. 2013 Dec 26;369(26):2472-4
pubmed: 24369072
JAMA. 2012 Apr 11;307(14):1513-6
pubmed: 22419800
JAMA. 2015 Jul 28;314(4):375-83
pubmed: 26219055
Ann Intern Med. 2017 Mar 07;166(5):341-353
pubmed: 28114600

Auteurs

Logan Trenaman (L)

Centre for Health Evaluation and Outcome Sciences, St Paul's Hospital, Vancouver, British Columbia, Canada.
Center for Healthcare Policy and Research, University of California, Davis, Sacramento.
Department of Public Health Sciences, University of California, Davis.

Mark Harrison (M)

Centre for Health Evaluation and Outcome Sciences, St Paul's Hospital, Vancouver, British Columbia, Canada.
Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Jeffrey S Hoch (JS)

Center for Healthcare Policy and Research, University of California, Davis, Sacramento.
Department of Public Health Sciences, University of California, Davis.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH